STI1 Activators
STI1 activators, representing a unique chemical class, have emerged as key players in the modulation of the protein STI1, also known as stress-inducible protein 1. The exploration of these activators involves a meticulous investigation into the methods governing the activation of STI1, focusing on elucidating the intricate signaling pathways and molecular interactions that contribute to the regulation of STI1 expression. Stress-induced-phosphoprotein 1 Activators encompass a variety of chemical compounds that functionally enhance Stress-induced-phosphoprotein 1 by intricately modulating the activity of its associated chaperone, Hsp90. Geldanamycin fortifies the role of Stress-induced-phosphoprotein 1 in the protein folding machinery by binding to Hsp90, thereby stabilizing the protein complex that Stress-induced-phosphoprotein 1 is part of. This stabilization is critical as it directly escalates the co-chaperone activity of Stress-induced-phosphoprotein 1. Similarly, Radicicol, by inhibiting Hsp90, necessitates an increased affinity and interaction of Stress-induced-phosphoprotein 1 with client proteins, which in turn, amplifies its co-chaperone functions.
The Hsp90 inhibitors such as 17-AAG, 17-DMAG, and Novobiocin, by disrupting Hsp90 chaperone cycles, indirectly elevate the demand and utilization of Stress-induced-phosphoprotein 1 in maintaining protein homeostasis. These inhibitors operate on a compensatory principle, where the inhibition of one component of the chaperone machinery escalates the activity of its partners, in this case, Stress-induced-phosphoprotein 1. The functional activity of Stress-induced-phosphoprotein 1 is further influenced by a range of Hsp90 inhibitors including CCT018159, PU-H71, BIIB021, SNX-2112, Luminespib, and Ganetespib. Each of these compounds, by disrupting the normal functions of Hsp90, indirectly potentiates the action of Stress-induced-phosphoprotein 1, which compensates for the loss of Hsp90 activity by enhancing its own chaperoning role.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin binds to Hsp90, a chaperone protein that interacts with Stress-induced-phosphoprotein 1, stabilizing its conformation and enhancing its co-chaperone activity in protein folding and stabilization processes. | ||||||
Radicicol | 12772-57-5 | sc-200620 sc-200620A | 1 mg 5 mg | $90.00 $326.00 | 13 | |
Radicicol functions as an Hsp90 inhibitor. Since Stress-induced-phosphoprotein 1 acts as a co-chaperone with Hsp90, the inhibition of Hsp90 can lead to an increased affinity of Stress-induced-phosphoprotein 1 for client proteins, indirectly enhancing its co-chaperoning role. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG inhibits Hsp90, which in turn can enhance the role of Stress-induced-phosphoprotein 1 in the chaperone complex due to compensatory mechanisms that maintain protein homeostasis. | ||||||
17-DMAG | 467214-20-6 | sc-202005 | 1 mg | $201.00 | 8 | |
Similar to other Hsp90 inhibitors, 17-DMAG enhances the activity of Stress-induced-phosphoprotein 1 by disrupting the normal Hsp90 functions, thereby potentially increasing the demand for Stress-induced-phosphoprotein 1's co-chaperone activity. | ||||||
Novobiocin | 303-81-1 | sc-362034 sc-362034A | 5 mg 25 mg | $96.00 $355.00 | ||
Novobiocin is a coumarin antibiotic that also acts as an Hsp90 C-terminal inhibitor, which may lead to enhanced interaction between Hsp90 and Stress-induced-phosphoprotein 1, increasing its functional activity. | ||||||
CCT128930 | 885499-61-6 | sc-364459 sc-364459A | 5 mg 10 mg | $153.00 $286.00 | 2 | |
CCT018159 is a small molecule inhibitor of Hsp90, which can indirectly enhance the functional role of Stress-induced-phosphoprotein 1 by increasing its requirement in the chaperone cycle. | ||||||
Salinomycin | 53003-10-4 | sc-253530 sc-253530C sc-253530A sc-253530B | 5 mg 10 mg 25 mg 100 mg | $159.00 $236.00 $398.00 $465.00 | 1 | |
PU-H71 is an Hsp90 inhibitor that could indirectly increase the functional activity of Stress-induced-phosphoprotein 1 by disrupting the Hsp90 chaperone cycle, leading to a compensatory increase in Stress-induced-phosphoprotein 1 activity. | ||||||
BIIB 021 | 848695-25-0 | sc-364434 sc-364434A | 5 mg 25 mg | $128.00 $650.00 | ||
BIIB021 is an orally bioavailable Hsp90 inhibitor that can indirectly enhance the functional activity of Stress-induced-phosphoprotein 1 by perturbing the Hsp90 chaperone machinery. | ||||||
NVP-AUY922 | 747412-49-3 | sc-364551 sc-364551A sc-364551B sc-364551C sc-364551D sc-364551E | 5 mg 25 mg 100 mg 250 mg 1 g 5 g | $150.00 $263.00 $726.00 $1400.00 $2900.00 $11000.00 | 3 | |
Luminespib is an isoxazole-based Hsp90 inhibitor that may enhance the functional activity of Stress-induced-phosphoprotein 1 by causing a compensatory increase in its activity due to Hsp90 inhibition. | ||||||
Ganetespib | 888216-25-9 | sc-364496 sc-364496A | 10 mg 250 mg | $268.00 $1020.00 | ||
Ganetespib is a triazolone-containing Hsp90 inhibitor that, by hindering Hsp90 function, may indirectly increase the requirement for Stress-induced-phosphoprotein 1 co-chaperone activity. | ||||||